Abeona Therapeutics opened lower at $2.28, compared with its previous close of $2.30. In the last trading session, the stock traded between $2.22 and $2.35. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Abeona Therapeutics is now worth
$ 9.77
Resulting in a loss of
$ 90.23 (90.23%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.02 (-0.65%)
Day High
$2.35
Day Low
$2.22
Day Open
$2.28
Prev Close
$2.30
Volume
22,66,983
1W Return
-45.79%
1M Return
-53.32%
3M Return
-69.11%
6M Return
-61.01%
1Y Return
-45.20%
Market Cap ($ Mn)
131
PE Ratio
-
PB Ratio
2.65
PEG Ratio
-
ROE
61.42%
ROCE
44.28%
EPS (TTM)
$-0.08
1 Week
-45.79%
1 Month
-53.32%
3 Months
-69.11%
6 Months
-61.01%
9 Months
-54.84%
HC Wainwright maintains Buy on Abeona Therapeutics, cuts target to $18
HC Wainwright & Co. maintains a Buy rating on Abeona Therapeutics. Price target lowered from $20 to $18 by analyst Raghuram Selvaraju. Investment thesis remains positive despite reduced valuation expectations.
TodayAbeona Therapeutics Q3FY27 results: EPS beats estimate, sales miss consensus
Q3 2026 net product revenue rose 18% sequentially to $13.5 million, missing consensus estimates. EPS of $(0.08) beat analyst expectations of $(0.15) by 46.67%. Company acquired ABO-801 for eosinophilic esophagitis with $20 million in stock and milestone payments. Secured $30 million in private placement financing from institutional investors including Nantahala Capital.
3 days agoAbeona Therapeutics grants 5,100 restricted shares to new employees
Abeona Therapeutics granted 5,100 restricted shares to two new non-executive employees. Awards were approved on October 31, 2026, under Nasdaq Listing Rule 5635(c)(4). Shares vest in one-third annual installments over three years, contingent on continued employment.
10 days agoAbeona Therapeutics grants 7,200 restricted shares to new employees
Abeona Therapeutics granted 7,200 restricted shares to two new non-executive employees. Awards were approved by the Compensation Committee on September 30, 2026. Shares vest in one-third increments annually over three years. Grants issued under Nasdaq Listing Rule 5635(c)(4) as employment inducement.
1mo agoPomerantz investigates Abeona Therapeutics over securities fraud claims
Pomerantz LLP investigates Abeona Therapeutics for securities fraud. Stock fell 14.95% to $6.35 on August 13, 2026. Revenue recognition issue cited for one of five ZEVASKYN treatments. Investigation focuses on unlawful business practices by officers/directors.
1mo agoAbeona shares rise 3.8% after FDA approves licensed gene therapy
Abeona shares rose 3.76% to $5.80 following FDA approval of FAYUVI. Abeona earns mid-single-digit royalties and up to $30 million in milestones from FAYUVI sales. University of Florida Health activated as eighth ZEVASKYN treatment center. Cantor Fitzgerald raises price target to $30; Roth Capital initiates with Buy.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Abeona Therapeutics is now worth
$ 9.77
Resulting in a loss of
$ 90.23 (90.23%)
Note: Past profits do not guarantee future returns.
